Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCR1 | P32246 | 1/20 | 0.60 |
| ▸ | CCR8 | P51685 | 1/20 | 0.60 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.52 |
| ▸ | METAP2 | P50579 | 1/20 | 0.43 |
| ▸ | TGFBR1 | P36897 | 8/20 | 0.42 |
| ▸ | NOS3 | P29474 | 1/20 | 0.40 |
| ▸ | NOS2 | P35228 | 1/20 | 0.40 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.39 |
| ▸ | MAPK14 | Q16539 | 3/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | RAB9A | P51151 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13483700 | 0.91 | CCR1 (0.71) | CCR1CCR8CYP2A6METAP2TGFBR1 | |
| SCHEMBL19009474 | 0.91 | L3MBTL1 (0.50) | CCR1CCR8CYP2A6TGFBR1L3MBTL1 | |
| SCHEMBL16189316 | 0.90 | CCR1 (0.58) | CCR1CCR8CYP2A6METAP2TGFBR1 | |
| SCHEMBL19009654 | 0.87 | CCR1 (0.46) | CCR1CCR8CYP2A6TGFBR1MAPK14 | |
| SCHEMBL19543719 | 0.86 | CCR1 (0.48) | CCR1CCR8CYP2A6TGFBR1L3MBTL1 | |
| SCHEMBL14168736 | 0.85 | CCR1 (0.62) | CCR1CCR8CYP2A6METAP2TGFBR1 | |
| SCHEMBL17932789 | 0.85 | CCR1 (0.52) | CCR1CCR8CYP2A6METAP2TGFBR1 | |
| SCHEMBL16189074 | 0.85 | CCR1 (0.52) | CCR1CCR8CYP2A6TGFBR1L3MBTL1 | |
| SCHEMBL16189377 | 0.85 | CCR1 (0.52) | CCR1CCR8CYP2A6METAP2TGFBR1 | |
| SCHEMBL16189355 | 0.85 | CCR1 (0.52) | CCR1CCR8CYP2A6TGFBR1L3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11329230-B2 | Organic light-emitting device | SAMSUNG DISPLAY CO., LTD. (KR) | 2022-05-10 | — | — | US | disclosed |
| US-20170317294-A1 | ORGANIC LIGHT-EMITTING DEVICE | SAMSUNG DISPLAY CO., LTD. (KR) | 2017-11-02 | — | — | US | disclosed |
| US-20170317294-A1 | ORGANIC LIGHT-EMITTING DEVICE | SAMSUNG DISPLAY CO., LTD. (KR) | 2017-11-02 | — | — | US | disclosed |
| US-20170179402-A1 | ORGANIC LIGHT-EMITTING DEVICE | SAMSUNG DISPLAY CO., LTD. (KR) | 2017-06-22 | — | — | US | disclosed |
| US-20170179402-A1 | ORGANIC LIGHT-EMITTING DEVICE | SAMSUNG DISPLAY CO., LTD. (KR) | 2017-06-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11329230-B2 | Organic light-emitting device | EML4, SUN2, TRPA1 | CCR1 2925/4885CCR8 2616/4885CYP2A6 1675/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.